Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioma 2Brain Neoplasms 2Waldenstrom Macroglobulinemia 1Unspecified Adult Solid Tumor, Protocol Specific 1Solid Tumors 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Glioblastoma 1Fallopian Tube Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 44Radiotherapy 20Magnetic Resonance Spectroscopy 13Irinotecan 13Carboplatin 11Bevacizumab 11Filgrastim 9Surgical Procedures, Operative 7Procarbazine 6sargramostim 5Vincristine 5Imatinib Mesylate 5Etoposide 5Erlotinib Hydrochloride 5Carmustine 5Biopsy 5etoposide phosphate 4Peripheral Blood Stem Cell Transplantation 4Lomustine 4Immunohistochemistry 4Cyclophosphamide 42-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 4temsirolimus 3poly ICLC 3aldesleukin 3Thalidomide 3Surveys and Questionnaires 3Radiation 3Polymerase Chain Reaction 3Gadolinium DTPA 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Oligodendroglioma × perifosine × Clear all
NCT02238496 2023-05-25

Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas

Columbia University

Phase 1 Completed
10 enrolled
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡